GYRE today
$4.20-$0.06 (-1.41%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minStrong Bearish
5 minExpanding
Daily trend turns down below $2.98
Key levels
Resistance$5.70
Resistance$4.50
Support$3.97
Support$2.98
Latest news & SEC filings
AnalystH.C. Wainwright keeps Buy rating on Gyre Therapeutics
EarningsGyre Therapeutics Posts Q3 2026 Results, Business Update
All GYRE news →About Gyre Therapeutics
Gyre Therapeutics develops oral medicines aimed at scarring and inflammation in internal organs. Its Chinese arm, Gyre Pharmaceuticals, sells treatments for lung scarring and for blood and liver complications tied to chronic liver disease, including pirfenidone, nintedanib, and avatrombopag. The company is testing Hydronidone for liver scarring, F573 for sudden liver failure, F230 for high blood pressure in the lung arteries, and F528 for chronic obstructive lung disease. It runs operations in China and the United States, with its American base in San Diego, California.
Based on the company's 10-K filed Mar 13, 2026.
Nasdaq · Healthcare
GYRE THERAPEUTICS, INC. (GYRE)
What Is the Price Target for GYRE?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is GYRE a Buy or Sell Right Now?
Thesis
- •Revenue growing 10.2% YoY with SLOWING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GYRE.
Start Free Trial →Is GYRE Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B
Fair Value
$2.80
11
Moat Score
NONE
4/9
Piotroski Score
9.4
Altman Z-Score
What Is Smart Money Doing with GYRE?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Ye Weiguo | officer | Buy | 2,800 | $2K | Jun 11, 2026 |
| Ye Weiguo | officer | Sale | 2,800 | $17K | Jun 11, 2026 |
| Ye Weiguo | officer | Buy | 6,418 | $5K | Jun 10, 2026 |
| Ye Weiguo | officer | Sale | 6,418 | $40K | Jun 10, 2026 |
| Ye Weiguo | officer | Buy | 14,500 | $11K | Jun 9, 2026 |
| Ye Weiguo | officer | Sale | 14,500 | $89K | Jun 9, 2026 |
| Ye Weiguo | officer | Buy | 15,401 | $12K | Jun 5, 2026 |
| Ye Weiguo | officer | Sale | 15,401 | $99K | Jun 5, 2026 |
| Ye Weiguo | officer | Buy | 19,575 | $15K | Jun 4, 2026 |
| Ye Weiguo | officer | Sale | 19,575 | $120K | Jun 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GYRE Growth Story
Revenue YoY
10.2%
3yr Revenue CAGR
4.5%
EPS Growth YoY
-60%
FCF Growth YoY
97.0%
Revenue Trend
SLOWING
Dark Pool Trades for GYRE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GYRE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:46:32 | $4.20 | 3,999 | $$17K | SELL |
| 14:45:06 | $4.20 | 4,094 | $$17K | SELL |
| 14:43:08 | $4.26 | 5,000 | $$21K | SELL |
| 14:40:03 | $4.25 | 3,530 | $$15K | SELL |
| 21:00:14 | $4.26 | 1,200 | $$5K | SELL |
5 dark pool trades shown · $$75K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for GYRE THERAPEUTICS, INC. (GYRE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GYRE — frequently asked questions
What is GYRE stock price today?
GYRE THERAPEUTICS, INC. (GYRE) is at $4.20, down 1.41% (-$0.06) at the Nov 12, 2026 close.
Why is GYRE stock moving today?
Latest GYRE news — Nov 7, 2026: H.C. Wainwright keeps Buy rating on Gyre Therapeutics · Nov 5, 2026: Gyre Therapeutics Posts Q3 2026 Results, Business Update
What do analysts rate GYRE?
Analyst ratings for GYRE: 3 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did GYRE beat earnings?
GYRE last reported on Aug 7, 2026: EPS -$0.12 vs -$0.06 expected — a miss of 111.6%.
Does GYRE pay a dividend?
GYRE does not currently pay a dividend.
What are GYRE support and resistance levels?
Support: $3.97, $2.98. Resistance: $4.50, $5.70, $6.46.
What are insiders doing with GYRE?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on GYRE?
Nov 7, 2026: H.C. Wainwright keeps Buy rating on Gyre Therapeutics · Nov 5, 2026: Gyre Therapeutics Posts Q3 2026 Results, Business Update